

Smart drugs to protect neurons

ENCEFA is a startup of the “Brain and Spine institute” (ICM), founded in 2016 and located at the Pitié Salpêtrière Hospital.




The objective of ENCEFA is to **develop new neuro-protective molecules**.



A NEW, POWERFUL, MECHANISM OF ACTION

How can ENCEFA meet this challenge, while no effective neuroprotective treatment is available to patients yet?

1- Understand: while the multifactorial nature of neurodegenerative diseases is now validated by the scientific community, it is very **tricky to identify a molecule acting on such different mechanisms**. Thus, the current method to discover a molecule is to focus on one of these factor, considered as essential, and bet that the selected molecule (designed to be efficient against this factor) will be neuroprotective in a clinical setting. This partial approach is certainly insufficient given the complexity of the disease.



2- Propose: ENCEFA's molecules are acting through a new, revolutionary, neuroprotective Mechanism Of Action (MOA). This MOA is the **culmination of more than 8 years of work within the ICM's Laboratories**. Located at the crossroad of the pathological cellular mechanisms, molecules acting through this MOA are effective against most of them.

Our compounds, by targeting this pathway, have the potential to become game-changing players in the area of neurodegenerative diseases and aging



TWO DEVELOPMENT PROGRAMS

ENCEFA capitalizes on its unprecedented mechanism of action (MOA) via two highly promising programs:

- **EN001 program**, that offers an exceptional neuroprotective potential:

A new molecule, named EN001, acting through this unprecedented MOA **has already shown exceptional results against Parkinson's disease, proven on highly relevant in vitro models**. EN001 is patented by ICM which has granted an exclusive license to ENCEFA.

- **R&D program**, to strengthen our pipeline:

On the one hand, R&D of **other molecules** acting through this unprecedented MOA (including repurposed ones), and, on the other hand, test of the effectiveness of this new mechanism on **other pathologies**.

Considering market topic, the estimated turnover of the first neuroprotective treatment targeting Parkinson's disease is estimated at USD 7 to 10 billion per year.

ENCEFA's challenge is to develop these two programs as quick as possible to finally bring hope to patients suffering from Parkinson's disease, and perhaps even beyond.